天津医药

天津医药 ›› 2016, Vol. 44 ›› Issue (2): 200-204.doi: 10.11958/58911

• 临床研究 • 上一篇    下一篇

Ⅳ期维吾尔族 NSCLC 患者 EML4-ALK、 EGFR 基因突变状态及生存分析

王强 1， 张峤 1， 曹燕珍 2， 陶洁 1， 单莉 1△   

  1. 1新疆医科大学附属肿瘤医院肺内科一病区 （邮编830011）， 2病理科
  • 收稿日期:2015-05-08 修回日期:2015-07-07 出版日期:2016-02-15 发布日期:2016-02-15
  • 通讯作者: △通讯作者 E-mail： shanlinew319@163.com E-mail:taojie0309@163.com
  • 基金资助:
    吴阶平医学基金会临床科研专项资助 （320.6799.1130）

EML4-ALK and EGFR mutation status and survival analysis in Uygur with stage Ⅳ NSCLC

WANG Qiang1， ZHANG Qiao1， CAO Yanzhen2， TAO Jie1， SHAN Li1△#br#   

  1. 1 Department of Medical Oncology, 2 Department of Pathology, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi 830011, China
  • Received:2015-05-08 Revised:2015-07-07 Published:2016-02-15 Online:2016-02-15
  • Contact: △Corresponding Author E-mail： shanlinew319@163.com E-mail:taojie0309@163.com

PDF (PC)

4287

摘要： 目的 探讨棘皮动物微管样蛋白 4-间变淋巴瘤激酶 （EML4-ALK） 和表皮生长因子受体 （EGFR） 基因突变状态与未经系统酪氨酸激酶抑制剂（TKIs）治疗的Ⅳ期维吾尔族非小细胞肺癌（NSCLC）患者长期生存的关系。方法 收集 97 例未经 TKIs 治疗的Ⅳ期维吾尔族 NSCLC 患者的组织标本， 分别运用 FISH 及 ARMS 方法检测 EML4- ALK 基因融合及 EGFR 基因突变状态并进行生存分析。结果 97 例Ⅳ期维吾尔族 NSCLC 组织中， 6 例 （6.2%） 存在 EML4-ALK 基因融合， 26 例（26.8%）存在 EGFR 基因突变。生存分析显示，EML4-ALK 基因融合患者与 EML4- ALK 基因未融合患者总生存期（OS）差异无统计学意义（P=0.941）， EGFR 基因突变患者与 EGFR 野生型患者 OS 比较差异无统计学意义 （P=0.607）。EGFR/EML4-ALK 综合突变对Ⅳ期维吾尔族 NSCLC 患者长期生存发现， EGFR 突变型组、 EML4-ALK 阳性组、 EML4-ALK 阴性+EGFR 野生型组患者中位 OS 分别为 17.7、 17.3、 16.2 个月， 差异无统计学意义（P=0.915）。结论 在排除 TKIs 治疗影响的情况下， EML4-ALK 融合基因与 EGFR 基因突变状态尚不能作为评估Ⅳ期维吾尔族 NSCLC 患者预后的独立因素。

关键词: 癌, 非小细胞肺, 受体, 表皮生长因子, 突变, 维吾尔族, 非小细胞肺癌, 棘皮动物微管样蛋白 4-间变淋巴 瘤激酶, 生存分析

Abstract: Objective To investigate the relationship between the echinoderm microtubule associated protein like 4- anaplastic lymphoma kinase (EML4-ALK) and epithelial growth factor receptor (EGFR) mutation status and overall survival (OS) in Uygur patients with stage Ⅳ non-small cell lung cancer (NSCLC) who did not accept tyrosine kinase inhibitor treatment. Methods Totally 97 tissue samples were collected from Uygur patients with stage Ⅳ NSCLC who did not accept tyro⁃ sine kinase inhibitor treatment. EML4-ALK fusion gene and EGFR mutation status were detected by using FISH and ARMS methods. The survival rates were analysed. Results In 97 tissue samples, EML4-ALK fusion genes were found in 6 (6.2%) samples, EGFR mutations were found in 26 (26.8%) samples. The survival analysis showed that there was no significant difference in OS between EML4-ALK fusion gene group and no EML4-ALK fusion gene group (P=0.941). There was no significant difference in OS between EGFR mutation group and wild-type EGFR group (P=0.607). The values of median OS were 17.7 months, 17.3 months and 16.2 months for EGFR mutant group, EML4-ALK positive group and EML4-ALK negative+ EGFR wild-type group, and thre was no significant difference between them (P=0.915). Conclusion Excluding the thera⁃ peutic influence in TKIs, EML4-ALK fusion gene and EGFR mutation status of tumor tissue can not be used as an indepen⁃ dent factor in assessing the prognosis in Uygur patients with stage Ⅳ NSCLC.

Key words: carcinoma, non-small-cell lung, receptor, epidermal growth factor, mutation, UYGUR NATIONALITY, non-small cell lung cancer, EML4-ALK, survival analysis